Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults
Main finding · OsteoporosisResult — go to the resultRelative risk 0.48 95% CI 0.43–0.52Authors' conclusion
GLP-1 RA use was associated with favorable musculoskeletal outcomes, including lower risks of osteoporosis and fractures, in nondiabetic adults with obesity compared with other obesity medications.
Study context
- Population
- Nondiabetic adults ≥50 years with obesity, TriNetX18,062 GLP-1 RA users matched
- Exposure
- GLP-1 RA vs non-GLP-1 obesity medications
- Outcome
- Incident osteoporosis
Methodological details1:1 propensity score matched, TriNetX data
- 1:1 propensity score matched
- TriNetX data
Main finding
Osteoporosis
Relative risk
0.48
95% CI 0.43–0.52
GLP-1 RAvs Non-GLP-1 medication
RR 0.48 (95% CI 0.43–0.52)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | RR (95% CI) | |
|---|---|---|
| Major osteoporotic fracturesNNT = 88 | 0.15 (0.11–0.22) | |
| Cervical disc degenerationNNT = 63 | 0.34 (0.28–0.41) | |
| Thoracolumbar disc diseaseNNT = 20 | 0.36 (0.33–0.40) | |
| OsteoarthritisNNT = 9 | 0.45 (0.43–0.48) | |
| 0.10.31310Relative risk (log scale) |
Subgroups and sensitivity analyses
- Protective associations consistent across age, sex, BMI and drug subtype subgroups and robust in sensitivity analyses
Original publication
Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults. Obesity (Silver Spring). Published 1 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →